News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
285,186 Results
Type
Article (15055)
Company Profile (303)
Press Release (269822)
Multimedia
Podcasts (79)
Webinars (11)
Section
Business (80479)
Career Advice (162)
Deals (13472)
Drug Delivery (39)
Drug Development (51584)
Employer Resources (32)
FDA (5968)
Job Trends (5374)
News (146837)
Policy (10280)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Standard (2)
Academia (928)
Accelerated approval (20)
Adcomms (15)
Allergies (81)
Alliances (21921)
ALS (126)
Alzheimer's disease (1034)
Antibody-drug conjugate (ADC) (241)
Approvals (6168)
Artificial intelligence (261)
Autoimmune disease (115)
Automation (10)
Bankruptcy (105)
Best Places to Work (4769)
BIOSECURE Act (6)
Biosimilars (100)
Biotechnology (233)
Bladder cancer (110)
Brain cancer (46)
Breast cancer (343)
Cancer (3203)
Cardiovascular disease (240)
Career advice (147)
Career pathing (7)
CAR-T (232)
CDC (5)
Cell therapy (611)
Cervical cancer (14)
Clinical research (44415)
Collaboration (1163)
Company closure (2)
Compensation (604)
Complete response letters (40)
COVID-19 (1113)
CRISPR (87)
C-suite (556)
Cystic fibrosis (112)
Data (4385)
Denatured (15)
Depression (92)
Diabetes (260)
Diagnostics (1381)
Digital health (10)
Diversity (5)
Diversity, equity & inclusion (10)
Drug discovery (188)
Drug pricing (48)
Drug shortages (3)
Duchenne muscular dystrophy (213)
Earnings (31966)
Editorial (25)
Employer branding (4)
Employer resources (30)
Events (52505)
Executive appointments (626)
FDA (7757)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (9)
Frontotemporal dementia (22)
Funding (987)
Gene editing (185)
Generative AI (21)
Gene therapy (492)
GLP-1 (504)
Government (1169)
Grass and pollen (3)
Guidances (166)
Healthcare (6757)
HIV (18)
Huntington's disease (43)
IgA nephropathy (74)
Immunology and inflammation (201)
Immuno-oncology (40)
Indications (68)
Infectious disease (1217)
Inflammatory bowel disease (156)
Inflation Reduction Act (10)
Influenza (38)
Intellectual property (167)
Interviews (18)
IPO (7448)
IRA (12)
Job creations (872)
Job search strategy (129)
JPM (40)
Kidney cancer (9)
Labor market (22)
Layoffs (252)
Leadership (9)
Legal (1403)
Liver cancer (44)
Longevity (11)
Lung cancer (430)
Lymphoma (264)
Machine learning (26)
Management (7)
Manufacturing (391)
MASH (130)
Medical device (2693)
Medtech (2703)
Mergers & acquisitions (6654)
Metabolic disorders (731)
Multiple sclerosis (102)
NASH (13)
Neurodegenerative disease (231)
Neuropsychiatric disorders (70)
Neuroscience (1957)
Neurotech (1)
NextGen: Class of 2026 (2047)
Non-profit (886)
Now hiring (30)
Obesity (330)
Opinion (125)
Ovarian cancer (131)
Pain (104)
Pancreatic cancer (161)
Parkinson's disease (233)
Partnered (12)
Patents (302)
Patient recruitment (329)
Peanut (43)
People (26837)
Pharmaceutical (45)
Pharmacy benefit managers (6)
Phase 1 (15749)
Phase 2 (20588)
Phase 3 (13123)
Pipeline (3298)
Policy (90)
Postmarket research (863)
Preclinical (6620)
Press Release (30)
Prostate cancer (146)
Psychedelics (50)
Radiopharmaceuticals (238)
Rare diseases (649)
Real estate (1469)
Recruiting (12)
Regulatory (10129)
Reports (19)
Research institute (982)
Resumes & cover letters (18)
Rett syndrome (24)
RNA editing (21)
RSV (16)
Schizophrenia (123)
Series A (183)
Series B (135)
Service/supplier (1)
Sickle cell disease (78)
Special edition (18)
Spinal muscular atrophy (119)
Sponsored (15)
Startups (2012)
State (1)
Stomach cancer (5)
Supply chain (33)
Tariffs (18)
The Weekly (63)
Vaccines (335)
Venture capital (69)
Weight loss (174)
Women's health (25)
Worklife (2)
Date
Last 7 days (353)
Last 30 days (1174)
Last 365 days (18069)
2026 (1683)
2025 (18363)
2024 (20870)
2023 (22874)
2022 (27289)
2021 (28276)
2020 (23734)
2019 (16470)
2018 (11912)
2017 (13957)
2016 (11958)
2015 (14453)
2014 (10461)
2013 (7540)
2012 (7608)
2011 (7647)
2010 (7460)
Location
Africa (154)
Alabama (65)
Alaska (2)
Arizona (73)
Arkansas (5)
Asia (18565)
Australia (3190)
California (7212)
Canada (1840)
China (775)
Colorado (246)
Connecticut (252)
Delaware (247)
Europe (39651)
Florida (945)
Georgia (209)
Hawaii (2)
Idaho (18)
Illinois (396)
India (35)
Indiana (160)
Iowa (8)
Japan (225)
Kansas (80)
Kentucky (9)
Louisiana (7)
Maine (11)
Maryland (740)
Massachusetts (5627)
Michigan (110)
Minnesota (254)
Mississippi (3)
Missouri (35)
Montana (16)
Nebraska (5)
Nevada (32)
New Hampshire (21)
New Jersey (1686)
New Mexico (13)
New York (1827)
North Carolina (836)
North Dakota (7)
Northern California (3550)
Ohio (178)
Oklahoma (11)
Oregon (24)
Pennsylvania (1280)
Puerto Rico (9)
Rhode Island (25)
South America (216)
South Carolina (9)
Southern California (2851)
Tennessee (40)
Texas (911)
United States (23689)
Utah (96)
Virginia (137)
Washington D.C. (37)
Washington State (609)
West Virginia (1)
Wisconsin (45)
285,186 Results for "allogene therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T
January 9, 2026
·
10 min read
Press Releases
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences - February 5, 2026
February 5, 2026
·
2 min read
Press Releases
NK Cell Therapeutics Autologous vs. Allogeneic: Who Will Lead the Race to Commercialization? - Commentary by Unexakorea
February 6, 2026
·
1 min read
Press Releases
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences - November 10, 2025
November 11, 2025
·
2 min read
Press Releases
Allogene Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update
October 31, 2025
·
2 min read
Press Releases
Allogene Therapeutics Reports Third Quarter 2025 Financial Results and Business Update
November 6, 2025
·
10 min read
CAR-T
Allogene Scraps Immunosuppressive Antibody After Patient Death in Lymphoma Trial
The pivotal Phase II trial is testing Allogene’s CAR T candidate cemacabtagene ansegedleucel for large B-cell lymphoma. ALLO-647 was being used as a preparative lymphodepletion therapy.
August 4, 2025
·
1 min read
·
Tristan Manalac
Press Releases
Allogene Therapeutics Announces ALPHA3 Trial-in-Progress Poster Presentation at ASH Annual Meeting
November 4, 2025
·
6 min read
Press Releases
Cytora Therapeutics, Made Scientific, and Zeo ScientifiX Announce Partnership to Manufacture and Commercialize Cytora’s Allogeneic Stem Cell Therapy in the United States
January 7, 2026
·
9 min read
Press Releases
Allogene Therapeutics Announces Participation in Upcoming September 2025 Investor Conference
August 28, 2025
·
2 min read
1 of 28,519
Next
